Headline News
HUTCHMED, AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI® in Patients with MET-Driven Advanced Papillary Renal Cell Carcinoma
Recent Posts
- Alibaba Falls But These Stocks Are Striking Major Gains In Hong Kong As Hang Seng Rebounds
- Elon Musk Mocks Apple Polishing Cloth And Entices His Millions-Strong Twitter Following To ‘Blow The Whistle On Tesla!’
- These Dogecoin and Shiba Inu Knockoffs Are Striking Major Gains Today, With One Coin Named After Elon Musk’s Pet Up 530%
- Key Facebook Executive Behind Digital Currency And Wallet Project To Depart Company This Month
- Chris Cuomo Suspended By CNN: What You Need To Know
Recent Comments